serdemetan
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00676910)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- p53-binding protein Mdm-2ANTAGONIST
MDM2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
c1ccc2c(CCNc3ccc(Nc4ccncc4)cc3)c[nH]c2c1- Mol. weight
- 328.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2137530 ↗
Also known as
- jnj 26854165
- jnj-26854165
- jnj-26854165
- jnj-26854165
- serdemetan
- serdemetan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00676910 | Phase 1 | Nov 1, 2006 | Johnson and Johnson |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1